Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05074940 · ClinicalTrials.gov registry record · Phase 2
Amivantamab in Adenoid Cystic Carcinoma
A Phase 2 study of Salivary Gland Cancer, sponsored by Trisha Wise-Draper.
- Active
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 5
- Study locations
NCT05074940 is a Phase 2 study of Salivary Gland Cancer that is active but no longer recruiting, run by Trisha Wise-Draper. The registered enrollment target is 18 participants, below the 63-participant average among 8 other Salivary Gland Cancer trials with a reported enrollment target (71% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT05074940, a Phase 2 study of Salivary Gland Cancer, is active but no longer recruiting, sponsored by Trisha Wise-Draper.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of the study is to determine if treatment with amivantamab will be efficacious in patients with recurrent and metastatic adenoid cystic carcinoma.
Conditions Studied
Interventions
- DRUG Amivantamab
Study Locations (5)
California
- UC San Diego Moores Cancer Center - La Jolla
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- Rogel Cancer Center - University of Michigan Health - Ann Arbor
Missouri
- Washington University - School of Medicine in St. Louis - St Louis
Ohio
- University of Cincinnati Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2022-08-05 |
| Est. Completion | 2028-08-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05074940
The ClinicalTrials.gov registry entry for NCT05074940 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 63-participant average among 8 other Salivary Gland Cancer trials with a reported enrollment target (71% lower). The listed sponsor is Trisha Wise-Draper, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Salivary Gland Cancer appearing as the primary indexed condition, and to 1 intervention - of which Amivantamab is the first listed.
NCT05074940 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Massachusetts, Michigan.
Frequently Asked Questions
What is clinical trial NCT05074940 about?
NCT05074940 is a clinical study titled "Amivantamab in Adenoid Cystic Carcinoma". The purpose of the study is to determine if treatment with amivantamab will be efficacious in patients with recurrent and metastatic adenoid cystic carcinoma.
What is the current status of trial NCT05074940?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2022-08-05. Estimated completion is 2028-08-05.
What conditions does trial NCT05074940 study?
This clinical trial studies the following conditions: Salivary Gland Cancer.
What interventions are being tested in trial NCT05074940?
The interventions under investigation include: Amivantamab (DRUG).
Who is sponsoring clinical trial NCT05074940?
This trial is sponsored by Trisha Wise-Draper, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05074940 being conducted?
This trial has 5 study locations across California, Massachusetts, Michigan, Missouri, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Salivary Gland Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers
RECRUITING · Phase 2
-
Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
RECRUITING · Phase 2
-
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
RECRUITING · Phase 2
-
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors
ACTIVE NOT RECRUITING · Phase 2
-
Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.